PLUS1
Best deals to access real time data! |
|
SMALL CAP BASIC
Monthly Subscription
for only
|
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last: $ 9.16 ◊ 0.00 (0.00%) | |
| Company Name | Stock Ticker Symbol | Market | Type | ISIN | Company Description |
|---|---|---|---|---|---|
| Galectin Therapeutics Inc. | GALT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| +0.41 | +4.69% | 9.16 | 9.49 | 8.72 | 9 | 8.75 | 19:49:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 9.17 | 9.3 | 0.13 | 1.40% | 1 | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 14,318 | 3,312,648 | $ 9.1352 | $ 30.26M | 674.55k | 1.28 - 9.49 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:35:25 | formt | 100 | $9.16 | USD |
Galectin Therapeutics Inc. Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 345.7M | 37.74M | $ -16.24M | -0.49 | 0.00 | 31.89M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ 0.00 | 0.00% | - | 11.90% |
Galectin Therapeutics Inc. News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/18/2018 | 16:45 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/15/2018 | 16:05 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/15/2018 | 08:07 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/14/2018 | 19:34 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/14/2018 | 19:33 | Edgar (US Regulatory) | Amended Statement of Changes in Beneficial Ownership (4/a) |
| 6/14/2018 | 19:32 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/14/2018 | 16:35 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GALT Price Data
| Period † | Open | High | Low | VWAP | Min Vol | Max Vol | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|---|---|
| 1 Week | 6.25 | 9.49 | 5.79 | 7.7323 | 1M | 6M | 3M | 2.91 | 46.56% |
| 1 Month | 4.56 | 9.49 | 3.96 | 6.7366 | 214k | 6M | 1M | 4.6 | 100.88% |
| 3 Months | 4.7 | 9.49 | 3.1 | 5.3805 | 84k | 6M | 740k | 4.46 | 94.89% |
| 6 Months | 2.35 | 9.49 | 1.88 | 4.9137 | 84k | 6M | 720k | 6.81 | 289.79% |
| 1 Year | 2.4 | 9.49 | 1.28 | 3.9974 | 36k | 7M | 540k | 6.76 | 281.67% |
| 3 Years | 3.07 | 9.49 | 0.49 | 2.9014 | 13k | 8M | 377k | 6.09 | 198.37% |
| 5 Years | 4.09 | 19.1099 | 0.49 | 5.4469 | 7k | 8M | 368k | 5.07 | 123.96% |
Galectin Therapeutics Inc. Description
| Galectin Therapeutics, Inc. offers drug research & development to create new therapies for fibrotic disease & cancer. It has two compounds in development; one to be used in treatment of liver fibrosis & fatty liver disease & the other in cancer therapy. |
